On April 13, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will present eight scientific posters and one oral presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026 (booth #1537).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive AI-based analysis, and help translate findings into clinically relevant insights. By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application, with the potential to enable cutting-edge oncology therapy development and commercialization.
"Bringing together lab and clinical data is becoming foundational to modern oncology research," said Tony Zook, CEO at NeoGenomics. "Our collaborations with biopharma partners have allowed us to develop compelling research that we’re proud to present at AACR (Free AACR Whitepaper), showcasing how these insights can directly enhance therapy development and create optionality for providers and patients."
Presentations at AACR (Free AACR Whitepaper) include:
Oral presentation (Clinical Trials Mini Symposium: Focus on ctDNA): Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial
Monday, April 20, at 2:30–4:30 PM
Poster #1106: Rapid identification of comprehensive multi-omic protein and RNA biomarkers on a single FFPE tissue section using a novel integrated nCounter workflow
Sunday, April 19, at 2:00–5:00 PM | Section 43
Poster #1224: Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment
Sunday, April 19, at 2:00–5:00 PM | Section 47
Poster #1456: Paletrra AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training
Monday, April 20, at 9:00 AM–12:00 PM | Section 4
Poster #1993: Real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies
Monday, April 20, at 9:00 AM–12:00 PM | Section 23
Poster #4162: AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens
Tuesday, April 21, at 9:00 AM–12:00 PM | Section 3
Poster #8493: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
Tuesday, April 21, at 9:00 AM–12:00 PM | Section 20
Poster #6674: Metabolic reprogramming in advanced renal tumors contributes to a dysfunctional immune response and immune exhaustion within the tumor microenvironment
Tuesday, April 21, at 2:00–5:00 PM | Section 48
Poster #7263: Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing
Wednesday, April 22, at 9:00 AM–12:30 PM | Section 21
Attendees interested in learning more about NeoGenomics’ clinical and genomics insight capabilities can connect with the team onsite at booth #1537.
(Press release, NeoGenomics Laboratories, APR 13, 2026, View Source [SID1234664338])